MaxCyte (MXCT) (MXCT)
:MXCT
MXCT Stock Chart & Stats
$0.72
$0.03(3.92%)
―
--
Day’s Range― - ―
52-Week Range$0.64 - $2.96
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$73.56M
Enterprise Value$74.42M
Total Cash (Recent Filing)$103.04M
Total Debt (Recent Filing)$17.94M
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding106,674,010
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$2.87Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthConsistently high gross margins (~78%) indicate durable unit economics in instrument/consumable sales and services. Strong product-level margins provide long-term cushion for R&D and commercialization, helping sustain profitability potential as scale and utilization recover.
Balance Sheet & Cash ReservesA large cash balance with no debt and materially reduced burn materially extends runway and lowers solvency risk. This financial flexibility supports product launches, SPL negotiations and milestone monetization without urgent external financing, a durable strategic advantage.
Installed Base & Consumables RecurrenceInstalled base growth expands the addressable recurring consumables and service market. A larger installed footprint drives predictable repeat PA and service demand, underpinning recurring revenues and making long-term revenue visibility less dependent on one-off instrument sales.
Bears Say
Sustained Revenue DeclineMulti-year revenue contraction signals weakening commercial traction or customer utilization. Persistent top-line decline undermines operating leverage, makes fixed-cost absorption harder, and delays path to sustainable profitability absent durable demand recovery or new revenue streams.
Negative Operating Cash FlowRepeated negative operating and free cash flows indicate the business burns balance sheet resources to fund operations. Even with current cash buffer, ongoing negative cash generation threatens long-term independence and forces reliance on milestone receipts or external capital if revenue trends don't reverse.
SPL Concentration & Program LossesHeavy reliance on a small number of SPL partners creates concentration and execution risk; program exits materially reduce near-term milestone potential and PA demand. This structural customer concentration makes medium-term revenue outcomes tied to a few external program decisions.
MaxCyte News
MXCT FAQ
What was MaxCyte (MXCT)’s price range in the past 12 months?
MaxCyte (MXCT) lowest stock price was $0.64 and its highest was $2.96 in the past 12 months.
What is MaxCyte (MXCT)’s market cap?
MaxCyte (MXCT)’s market cap is $73.56M.
When is MaxCyte (MXCT)’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MaxCyte (MXCT)’s earnings last quarter?
Currently, no data Available
Is MaxCyte (MXCT) overvalued?
According to Wall Street analysts MaxCyte (MXCT)’s price is currently Undervalued.
Does MaxCyte (MXCT) pay dividends?
MaxCyte (MXCT) does not currently pay dividends.
What is MaxCyte (MXCT)’s EPS estimate?
MaxCyte (MXCT)’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MaxCyte (MXCT) have?
MaxCyte (MXCT) has 106,674,010 shares outstanding.
What happened to MaxCyte (MXCT)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MaxCyte (MXCT)?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.87 (― Downside)
$2.87 (― Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-24.06%
Trailing 12-Months
Asset Growth
-15.44%
Trailing 12-Months
Company Description
MaxCyte (MXCT)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Stock 12 Month Forecast
Average Price Target
$2.87
Ownership Overview
1.42%
Insiders
11.32%
Mutual Funds
23.12% Other Institutional Investors
55.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---